In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
CTS Tampa lab implements Dengue testing on behalf of a healthcare partner in an endemic area.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...